A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
AstraZeneca
M.D. Anderson Cancer Center
University Hospital, Grenoble
Dana-Farber Cancer Institute
Hellenic Cooperative Oncology Group
Pfizer
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Pfizer